Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer’s Eylea Sees Good Start In Japan Thanks To Partnering

This article was originally published in PharmAsia News

Executive Summary

Bayer's three new products – Eylea, Xarelto and Stivarga – are off to a good start in the marketplace, says interim pharma head Wolfgang Plischke. Eylea has 48% Japanese market share for wet AMD.

Advertisement

Related Content

Symonds Steps Down As Novartis CFO, Replaced By Insider Kirsch
Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC084149

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel